September 2019 pharmaceutical M&A round-up

1 October 2019

September is known as the back to school month, and biopharma dealmakers have clearly been back at their desks too, with some major acquisitions announced.

The biggest deal of the month belongs to Sumitomo Dainippon (TYO: 4506), the Japanese drugmaker, which is paying $3 billion to buy into the biopharma companies owned by Roivant Sciences, while perhaps the most ambitious in scope is US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) splashing out $950 million in a bid to 'transform the treatment paradigm for type 1 diabetes'.

Certain big pharma companies will have been most interested to see Danish CNS specialist Lundbeck (LUND: CO) entering the anti-CGRP migraine therapy race with a $1.95 billion acquisition, an area with intensifying competition.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK